Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $40.1 million versus the consensus estimate of $39.83 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.